Virbagen Omega (--) - Powder and solvent for suspension for injection
Virbagen Omega (--) - Powder and solvent for suspension for injection
Authorised
- Interferon omega, recombinant, feline
Product identification
Medicine name:
Virbagen Omega (--) - Powder and solvent for suspension for injection
Active substance:
- Interferon omega, recombinant, feline
Target species:
-
Dog
-
Cat
Route of administration:
-
Intravenous use
-
Subcutaneous use
Product details
Active substance and strength:
-
Interferon omega, recombinant, felinePresentation_strength:10 MU Reference:Hse Index:0
Pharmaceutical form:
-
Powder and solvent for suspension for injection
Withdrawal period by route of administration:
-
Intravenous use
- Dog
- Cat
-
Subcutaneous use
- Dog
- Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QL03AB
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Austria
-
Belgium
-
Bulgaria
-
Croatia
-
Cyprus
-
Czechia
-
Denmark
-
Estonia
-
Finland
-
France
-
Germany
-
Greece
-
Hungary
-
Iceland
-
Ireland
-
Italy
-
Latvia
-
Liechtenstein
-
Lithuania
-
Luxembourg
-
Malta
-
Netherlands
-
Norway
-
Poland
-
Portugal
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
Available in:
-
Austria
-
France
Package description:
- Packaging:Powder: vial (glass); solvent: vial (glass), Package_size:Powder: 1 vial + Solvent: 1 vial, Content:Powder: 10 MU; Solvent:1 ml
- Packaging:Powder: vial (glass); solvent: vial (glass), Package_size:Powder: 2 vials + Solvent: 2 vials, Content:Powder: 10 MU; Solvent: 1 ml
- Packaging:Powder: vial (glass); solvent: vial (glass), Package_size:Powder: 5 vials + Solvent: 5 vials, Content:Powder: 10 MU; Solvent: 1 ml
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Complete application (stand-alone) - Council Directive 81/851/EEC
Marketing authorisation holder:
- Virbac S.A.
Marketing authorisation date:
-
-
Manufacturing sites for batch release:
- VIRBAC
Responsible authority:
- European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Combined File of all Documents
English (PDF)
Download Published on: 23/11/2022
Bulgarian (PDF)
Published on: 23/11/2022
Croatian (PDF)
Published on: 23/11/2022
Czech (PDF)
Published on: 23/11/2022
Danish (PDF)
Published on: 23/11/2022
Dutch (PDF)
Published on: 23/11/2022
Estonian (PDF)
Published on: 23/11/2022
Finnish (PDF)
Published on: 23/11/2022
French (PDF)
Published on: 23/11/2022
German (PDF)
Published on: 23/11/2022
Greek (PDF)
Published on: 23/11/2022
Hungarian (PDF)
Published on: 23/11/2022
Icelandic (PDF)
Published on: 23/11/2022
Italian (PDF)
Published on: 23/11/2022
Latvian (PDF)
Published on: 23/11/2022
Lithuanian (PDF)
Published on: 23/11/2022
Maltese (PDF)
Published on: 23/11/2022
Norwegian (PDF)
Published on: 23/11/2022
Polish (PDF)
Published on: 23/11/2022
Portuguese (PDF)
Published on: 23/11/2022
Romanian (PDF)
Published on: 23/11/2022
Slovak (PDF)
Published on: 23/11/2022
Slovenian (PDF)
Published on: 23/11/2022
Spanish (PDF)
Published on: 23/11/2022
Swedish (PDF)
Published on: 23/11/2022
ema-puar-virbagen-omega-v-061-par-en.pdf
English (PDF)
Download Published on: 16/03/2023
How useful was this page?:
